日本新冠疫苗接种后肩部损伤相关疫苗不良反应(SIRVA)发病率的时间变化
该研究分析日本2021年2月17日至2023年3月12日被动不良反应报告,评估新冠疫苗接种后SIRVA发病率的时间变化及与性别、年龄和疫苗类型的关联。共分析433,538,539剂次接种,识别574例(宽标准)和76例(窄标准)SIRVA病例,最高三个月报告发病率为22.96例/百万剂次,发病率随时间下降,女性报告发病率约为男性两倍,不同疫苗类型间无显著差异。
要点
- SIRVA是三角肌肌内注射不当相关的可预防不良事件
- 新冠疫苗接种后SIRVA报告发病率随时间下降
- 女性SIRVA报告发病率约为男性两倍
核心结论
- SIRVA报告发病率随时间下降,可能反映新冠大规模接种中肌内注射技术的改进,但报告行为变化等其他因素也需考虑。
研究设计与样本
- 分析日本健康科学理事会2021年2月17日至2023年3月12日公开的被动不良反应报告,采用宽和窄两种SIRVA标准,计算每百万剂次SIRVA病例数和率比,覆盖9个三个月间隔。
主要发现
- 在433,538,539剂次接种中,识别574例(宽标准)和76例(窄标准)SIRVA病例。
- 最高估计三个月报告发病率为22.96例/百万剂次。
- SIRVA发病率随时间下降,尤其在第一个和第二个三个月间隔之间。
- 按两种标准,女性报告发病率均为男性的两倍。
- 宽标准下最高报告发病率见于35-39岁人群,窄标准下见于60-64岁人群;不同疫苗类型间SIRVA发病率无显著差异。
临床怎么用
- 应培训正确的肌内注射技术、监测不良事件并提高对SIRVA的认识,以进一步降低SIRVA发生率。
局限性
- 研究使用被动不良反应报告,报告行为变化可能影响发病率趋势解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Shoulder Injury Related to Vaccine Administration (SIRVA) is a rare but potentially preventable adverse event associated with improper intramuscular (IM) injections into the deltoid muscle. This study aimed to assess temporal changes in SIRVA incidence following universal COVID-19 vaccination in Japan and to examine the associations with sex, age, and vaccine type. METHODS: We analyzed publicly available passive adverse event reports from the Health Science Council in Japan between 2/17/2021 and 3/12/2023. Two SIRVA criteria (broad and narrow) were used. SIRVA cases per 1,000,000 doses and rate ratios were calculated across 9 three-month intervals. Subgroup analyses were conducted according to sex, age, and vaccine type (Pfizer or Moderna). RESULTS: Among the 433,538,539 vaccine doses administered, 574 (broad) and 76 (narrow) SIRVA cases were identified. The highest estimated three-month reporting incidence was 22.96 cases per 1,000,000 doses administered. The incidence of SIRVA declined over time, especially between the first and second three-month intervals. According to both criteria, the reporting incidence was twice as high in women. The highest reporting incidence was observed in individuals aged 35-39 (broad) and 60-64 years (narrow). No significant differences in SIRVA incidence were observed between the vaccine types. CONCLUSION: The temporal decline in SIRVA incidence may reflect improvements in the IM injection technique during the COVID-19 mass vaccination, but other factors including changes in reporting behavior should also be considered. Training in proper IM injection techniques, monitoring adverse events, and raising awareness of SIRVA are important to further reduce the incidence of SIRVA.
引用
- Kawada H, Shimazaki T, Yamauchi T, et al. Temporal changes in incidence of Shoulder Injury Related to Vaccine Administration (SIRVA) after COVID-19 vaccination. Vaccine. 2026. PMID: 42966041. doi:10.1016/j.vaccine.2026.129304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。